Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arrhythmia Research Technology (Arrhythmia) has successfully converted its proprietary signal-averaged electrocardiography (SAECG) software Predictor that runs on a single hardware based platform, ART 1200-EPX, to a customisable modular software product that is reconfigurable for a variety of hardware platforms.
Subscribe to our email newsletter
The conversion allows Predictor to be used with customer-specific electrocardiogram acquisition equipment to generate the signal-averaged ECG. The software can be easily customised to interface with a variety of Original Equipment Manufacturer (OEM) hardware. OEM customers can license Predictor and bundle it with other cardiac diagnostic software packages incorporated in their acquisition equipment.
The company said that a signal-averaged electrocardiogram detects cardiac microvolt signals. Signal averaging, which improves the signal to noise ratio, is a well-recognised technique for detecting and analysing such cardiac microvolt signals. High resolution acquisition equipment is used to collect the microvolt signals and transfer the data to an analytical system. ART’s patented Predictor software embedded in the system then filters and analyses the data to present the signal-averaged ECG for interpretation by a cardiologist.
James Rouse, president and CEO of Arrhythmia, said: We are very pleased to announce the availability of the Predictor SAECG analysis software to the OEM market. The patented methodology used in Predictor is considered by the American College of Cardiology and the American Heart Association to be the ‘Gold Standard’ in signal-averaged electrocardiography analysis.
“It is a very valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients. Predictor is currently being used in a National Institutes for Health (NIH) funded investigation into ‘Risk Stratification in MADIT II Type Patients’.”